Given the pivotal roles of KCCs and NKCC1 in determining the polarity of response to inhibitory neurotransmitters, they are emerging as attractive targets for developing therapeutic strategies to restore GABA inhibition for the treatment of various brain disorders and psychiatric conditions [46,47]. Here, SLC12A2 is linked to brain disorder.